1
|
Borrebaeck CAK. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer 2017; 17:199-204. [PMID: 28154374 DOI: 10.1038/nrc.2016.153] [Citation(s) in RCA: 252] [Impact Index Per Article: 36.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.
Collapse
Affiliation(s)
- Carl A K Borrebaeck
- Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village (Bldg 406), Lund University, 223 81 Lund, Sweden
| |
Collapse
|
2
|
Liang F, Qu H, Lin Q, Yang Y, Ruan X, Zhang B, Liu Y, Yu C, Zhang H, Fang X, Hao X. Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes. World J Surg Oncol 2015; 13:258. [PMID: 26311227 PMCID: PMC4551378 DOI: 10.1186/s12957-015-0642-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 07/03/2015] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Non-sentinel lymph node (NSLN) status prediction with molecular biomarkers may make some sentinel lymph node (SLN) positive breast cancer patients avoid the axillary lymph node dissection, but the available markers remain limited. METHODS SLN positive patients with and without NSLN invasion were selected, and genes differentially expressed or fused in SLN metastasis were screened by next-generation RNA sequencing. RESULTS Six candidates (all ER/PR+, HER2-, Ki-67 <20%) with metastatic SLNs selected from 305 patients were equally categorized as NSLN negative and positive. We identified 103 specifically expressed genes in the NSLN negative group and 47 in the NSLN positive group. Among them, FABP1 (negative group) and CYP2A13 (positive group) were the only 2 protein-encoding genes with expression levels in the 8th to 10th deciles. Using a false discovery rate threshold of <0.05, 62 up-regulated genes and 98 down-regulated genes were discovered in the NSLN positive group. Furthermore, 10 gene fusions were identified in this group with the most frequently fused gene being IGLL5. CONCLUSIONS The biomarkers screened in present study may broaden our understanding of the mechanisms of breast cancer metastasis to the lymph nodes and contribute to the axillary surgery selection for SLN positive patients.
Collapse
Affiliation(s)
- Feng Liang
- Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Fengtai District, Beijing, 100071, China.
| | - Hongzhu Qu
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, 1-104 Beichen West Road, Chaoyang District, Beijing, 100101, China.
| | - Qiang Lin
- Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Fengtai District, Beijing, 100071, China.
| | - Yadong Yang
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, 1-104 Beichen West Road, Chaoyang District, Beijing, 100101, China.
| | - Xiuyan Ruan
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, 1-104 Beichen West Road, Chaoyang District, Beijing, 100101, China.
| | - Bo Zhang
- Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Fengtai District, Beijing, 100071, China.
| | - Yi Liu
- Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Fengtai District, Beijing, 100071, China.
| | - Chengze Yu
- Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Fengtai District, Beijing, 100071, China.
| | - Hongyan Zhang
- General Hospital of Beijing Military Area, 5 Nanmencang, Dongcheng District, Beijing, 100700, China.
| | - Xiangdong Fang
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, 1-104 Beichen West Road, Chaoyang District, Beijing, 100101, China.
| | - Xiaopeng Hao
- Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Fengtai District, Beijing, 100071, China.
| |
Collapse
|
3
|
Mazouni C, Reitsamer R, Rimareix F, Stranzl H, Uzan C, Garbay JR, Delaloge S, Peintinger F. The positive non-sentinel status is not the main decisional factor for chemotherapy assignment in breast cancer with micrometastatic disease in the sentinel lymph node. J Surg Oncol 2012; 106:703-7. [PMID: 22674094 DOI: 10.1002/jso.23188] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Accepted: 05/15/2012] [Indexed: 01/16/2023]
Abstract
BACKGROUND Surgical and systemic treatment modalities for breast cancer (BC) patients with micrometastatic disease in the sentinel lymph node biopsy (SNB) are controversial. The aim of this study was to evaluate decisional factors associated with assignment of adjuvant chemotherapy (CT). PATIENTS AND METHODS In a retrospective multicentric European study we evaluated cases of primary BC patients who underwent SNB. Logistic regression (LR) and recursive partitioning analyses (RPA) were performed to determine factors associated with CT. RESULTS Of the 172 patients with micrometastatic disease, 39.5% received adjuvant CT. In the group treated with CT, patients tended to be younger (P = 0.001), with higher grade (P = 0.001) and HER2 positive tumors (P = 0.006) compared to patients without CT. In multivariate LR, age (P = 0.0027), high grading (P = 0.01) HER2 positivity (P = 0.03), and positive non-SN status (P = 0.03) were significantly associated with CT. RPA demonstrated that tumor grade, and not the non-SN status, was the first split in the partition tree followed by HER2 status, and non-SN status influencing the probability for CT administration. CONCLUSION High tumor grade is the main decisional factor followed by HER2 positivity and then by the positive non-SN status for CT in micrometastatic disease in the SN.
Collapse
Affiliation(s)
- Chafika Mazouni
- Department of Breast Medical and Surgical Oncology, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | |
Collapse
|